Allergy Therapeutics (LSE:AGY) Buyback Yield %: -0.35 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Allergy Therapeutics Buyback Yield %?

Allergy Therapeutics LSE:AGY -8.11% Buyback Yield % is -0.35 as of Jul. 16, 2026. The stock has 7 warning signs investors should review. Among 290 Drug Manufacturers companies, Allergy Therapeutics ranks better than 52.07% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Allergy Therapeutics's current buyback yield was -0.35%.

Allergy Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Buyback Yield % Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -96.77 -0.97 0.00

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.77 -0.97 12.04 0.00 -0.22

LSE:AGY vs ZTS, UTHR, VTRS: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergy Therapeutics Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Buyback Yield % falls into.


Allergy Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Allergy Therapeutics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 378.93198
=0.00%

Allergy Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1.494) / 675.5584
=-0.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -0.35 mean?
Allergy Therapeutics (LSE:AGY) has a Buyback Yield % of -0.35 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #139 out of 290 companies in the Drug Manufacturers industry, placing it in the top 47.9%.
Is Allergy Therapeutics' Buyback Yield % too high?
Allergy Therapeutics' current Buyback Yield % is -0.35. Based on the distribution chart, Allergy Therapeutics ranks #139 out of 290 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Allergy Therapeutics' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #139 out of 290 companies for Buyback Yield %. This puts Allergy Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Allergy Therapeutics and its competitors. Allergy Therapeutics's current Buyback Yield % is -0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 126.7% above its estimated fair value. The current Buyback Yield % is -0.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Buyback Yield % is -0.35 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).